There is no human dose of the Wolverine stack, because no human trial of the combination has been run.<\/p>\n
As of October 29, 2026, the only experiment that has put BPC-157 and TB-500 into one body used 32 rats, and its reported result was that the pair worked no better than either peptide alone. Charts rank, split and schedule two substances whose combined human record is a single animal study that undercuts the reason for combining them.<\/p>\n
We read what the sellers print, then went to the documents behind the claims: FDA’s bulk-substance file, the only combination study, and the systematic review that gathered every published human BPC-157 study.<\/p>\n
The stack is a nickname for BPC-157 plus TB-500, sold as one pre-mixed vial. One UK seller lists a 20 mg vial holding 10 mg of each peptide, describes it as a preparation “for controlled analytical and in-vitro experimentation,” and ships it with a reusable pen and needles in the box. The same page cites three references, and the third is a guide to the Wolverine stack that opens another clinic’s blog rather than a journal article.<\/p>\n
One US seller’s dosing guide states 250 micrograms of each peptide once daily as “the standard dose,” lists a larger figure as an “aggressive recovery dose,” builds a six-week cycle around it, and prints a discount code in the same article. The guide was live on October 29, 2026. It cites no human trial for those figures, because none exists.<\/p>\n
That is the loop a searcher walks into. A dosing chart is written to be crawled, a supplier is linked at the bottom, and the citation trail ends where the sales page begins. The third reference is another clinic’s blog, not a study.<\/p>\n
The one study that treated BPC-157 and TB-500 as a combination came out of Istanbul, published July 23, 2026 in Joint Diseases and Related Surgery<\/em>. Bi\u00e7er and colleagues took 32 male Sprague-Dawley rats, twelve weeks old and roughly 330 grams each, cut and repaired the Achilles tendon in each animal, and split them into four groups of eight: control, BPC-157 at 10 micrograms per kilogram per day, TB-500 at 60 micrograms per kilogram per day, and both peptides together. Treatment ran four weeks, injected into the abdomen rather than under the skin.<\/p>\n The TB-500 group carried a higher maximum load to failure than controls, and that difference reached statistical significance. The BPC-157 group scored numerically better on the tendon histology scales without reaching significance. The combination group, the one that mirrors what people buy, produced a lower Movin score than controls and no advantage over either single peptide. The authors wrote it plainly: “Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.”<\/p>\n They called their own work exploratory and asked for dose optimization and longer studies, and we will hold them to the higher standard they set. This is a rat model, an abdominal injection, a four-week window. Nothing in it is a human protocol, and nothing in it produces a milligram figure a person should follow. It is the only direct test of the stack’s central premise, and the combination did not beat either peptide alone.<\/p>\n Poolton, Minett and Kazmi published the most complete accounting of human BPC-157 evidence on October 8, 2026 in Acta Orthopaedica Belgica<\/em>. The review was registered in advance (PROSPERO CRD420261406325), searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to June 1, 2026, and applied the GRADE framework to what it found.<\/p>\n It found three studies and 30 people. Sixteen patients in a retrospective review of BPC-157 injected into the knee for pain. Twelve in a retrospective pilot of BPC-157 instilled into the bladder for interstitial cystitis. Two in a prospective pilot testing intravenous safety. Each study reported improvement in most participants with no treatment-related adverse events, and each was judged to be of poor methodological quality. Certainty of evidence was rated very low, with serious risk of bias, indirectness and imprecision.<\/p>\n Their conclusion is not ambiguous: BPC-157 “should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.” Thirty people, three papers, no control group that would separate the peptide from time and rest. That is the entire human file for half of the stack.<\/p>\n The other half has less. FDA’s page on bulk substances that may present significant safety risks carries a row for the TB-500 fragment: “FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment. FDA lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans.”<\/p>\n The BPC-157 row, on the same page, is a degree less blank and no more reassuring. FDA wrote that compounded drugs containing BPC-157 “may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization,” and that it “has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”<\/p>\n Both sit in the table titled “Bulk drug substances nominated but withdrawn,” which held 17 entries when we checked on October 29, 2026, current as of April 22, 2026. Withdrawn means the company that nominated the substance pulled it. It does not mean the agency cleared the peptide, and it does not mean a trial answered the question.<\/p>\n Some clinics sell an extended stack that adds CJC-1295 and ipamorelin. Those two carry a written warning. FDA’s file states: “FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”<\/p>\n Ipamorelin acetate gets a longer entry. FDA notes the potential for aggregation and peptide-related impurities, then adds: “A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.” The agency says it lacks sufficient information to know whether the drug would cause harm by other injectable routes.<\/p>\n We covered the CJC-1295 record in our breakdown of the FDA file on that peptide<\/a>. A four-peptide stack asks a patient to accept two unstudied peptides plus two more that the regulator has already tied to serious events, presented as one protocol with one price.<\/p>\n On October 29, 2026, a PubMed search for records naming both BPC-157 and TB-500 returned 11 papers. Ten are reviews, primers or commentaries about peptides in orthopedic and sports medicine. The eleventh is the rat study. No human trial of the combination is indexed, and no case series of the blend is indexed either.<\/p>\n ClinicalTrials.gov returned four registered studies for BPC-157 and zero for the Wolverine stack on the same date. Whatever is sold as a stack is not being studied as one.<\/p>\n We cannot give a safe dose of the Wolverine stack, because no study has established one in humans and the only animal study of the pair found no added benefit from combining them. We can tell you what the record holds: 30 people across three poor-quality BPC-157 studies, no human exposure data for TB-500 in FDA’s file, and one rat experiment that failed to show the stack beats a single peptide.<\/p>\n If a clinic offers the blend, the useful questions are the ones a chart cannot answer. Which trial is this protocol based on? Which pharmacy compounded the vial, and is that pharmacy licensed in your state? What is in the vial, at what strength, and can you see the certificate of analysis? Our guide to checking a peptide clinic before you book<\/a> walks through those in order.<\/p>\n Our directory<\/a> lists clinics by city, and we ask you to check each clinic’s license yourself rather than take a listing as an endorsement. We publish no clinic as verified, vetted or approved. The BPC-157 compound page<\/a> and the TB-500 compound page<\/a> carry each peptide’s regulatory history, and the compounds hub<\/a> indexes the rest. The FDA advisory-committee fight over these two substances is in our account of the peptide vote<\/a>, and the four dosage figures sold for TB-500 are traced to their documents in our TB-500 dosage breakdown<\/a>.<\/p>\n One honest gap: nothing published tells us how often the blend causes harm, because no one is counting. FDA’s adverse-event system depends on reports, and a product sold as research material arrives without a label, a dose, or a lot number a reporter can quote.<\/p>\n No. No human trial has tested BPC-157 and TB-500 together, so no dose has been established, compared against a placebo, or checked for safety in people. The figures on seller pages are commercial conventions, not study results.<\/p>\n A nickname for BPC-157 plus TB-500, sold as a pre-mixed vial, usually with equal amounts of each peptide. Some clinics sell a four-peptide version that adds CJC-1295 and ipamorelin. The name is borrowed from a comic character, and no version has been approved by FDA for human use.<\/p>\n It used weight-scaled doses given into the abdomen of rats for four weeks. There is no human protocol to compare against, so no conversion is meaningful, and we publish none. The study’s finding was that the combination gave no extra benefit over either peptide alone.<\/p>\n No. FDA has no approved product containing BPC-157 or the TB-500 fragment for any use. Both appear on FDA’s list of bulk drug substances nominated for compounding and later withdrawn by the nominator, and FDA states it lacks the information to know whether either would cause harm in humans.<\/p>\n That depends on the pharmacy, the state, and whether the substances qualify for lawful compounding, which we explain in our guide to the 503A rules<\/a>. A state-licensed pharmacy is not the same thing as an FDA-approved product, and a compounded vial is not reviewed for safety, effectiveness or quality before it reaches a patient.<\/p>\n FDA publishes no side-effect profile for either, because it says it lacks the information. The concerns in its file are immunogenicity from aggregation and peptide-related impurities, the difficulty of characterizing the raw ingredient, and, for TB-500, that no human exposure data have been submitted at all.<\/p>\n Start with our clinic directory<\/a>, then call and ask which trial the protocol follows and which licensed pharmacy compounded the vial. A clinic that cannot answer those two questions has no trial behind its protocol.<\/p>\n This page is educational information, not medical advice, a diagnosis, or a treatment recommendation. It does not recommend any peptide, medication, pharmacy, clinic, or treatment plan, and it makes no claim that any unapproved substance is safe or effective. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before they are marketed. Doses vary, and the decision about a prescription belongs to a licensed clinician who knows your history. Talk to your prescriber about your own situation, and see our full medical disclaimer<\/a>.<\/p>\nBPC-157: The Human Record Is Three Studies and 30 People<\/h2>\n
TB-500: FDA Found No Human Exposure Data at All<\/h2>\n
The Four-Peptide Version Adds the One FDA Already Flagged<\/h2>\n
What the Search Record Shows: 11 Papers, One Animal Study<\/h2>\n
Wolverine Stack Dosage: What We Can Say, and What Nobody Can<\/h2>\n
Frequently asked questions<\/h2>\n
Is there a standard Wolverine stack dosage?<\/h3>\n
What is the Wolverine stack?<\/h3>\n
Did the rat study use the same doses people are told to take?<\/h3>\n
Is the Wolverine stack FDA approved?<\/h3>\n
Can a compounding pharmacy legally make the Wolverine stack?<\/h3>\n
What side effects have been reported with BPC-157 and TB-500?<\/h3>\n
Where can I find a clinic that will answer these questions?<\/h3>\n
Sources<\/h2>\n
\n